Allergy news and updates

News and Trends 10 Dec 2015

Peanut Allergies? This Phase III Trial Could Mean an End to Nut-Related Anaphylaxis

Peanut allergy in children can be life-threatening, with safe treatment options available. Now DBV Technologies in Paris has a phase III transdermal patch which desensitizes the patient to peanuts, with fast-track FDA approval. The allergens in peanuts can stimulate an immune response to their presence, which can even result in life-threatening anaphylaxis (here is a […]

December 10, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 19 Sep 2015

Swiss Biotech Boom: Life sciences startups dominate top 100 awards

Exciting news for the Swiss biotech frontline! The TOP 100 Start-Up award is hosted by Startup.ch the Swiss start-up platform (through IFJ Institut für Jungunternehmen) in collaboration with the major paper Handelszeitung and PME Magazine, ranking the 100 most promising new start up companies. Of these 100, a whopping 68 of these start-ups are in the […]

September 19, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 23 Jun 2015

DBV Technologies to cure Peanut allergy

DBV Technologies plans the initiation of its phase III clinical trial for Viaskin Peanut, after a satisfactory conclusion of the phase II. The drug candidate already achieved a positive opinion from the Paediatric Committee of the European Medicines Agency. Both FDA and EMA desire to move forward with the development of what may be the […]

June 23, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 18 May 2015

Allergist Circassia grabs a couple of Asthma-Specialist companies

The allergy specialist Circassia will acquire two asthma-expert companies: Aerocrine and Prosonix. The British company, which performed the biggest of the fifteen European biotech IPOs in 2014, intends to become a self-sustaining biopharma by focusing on allergies and asthma. The purchases will optimize the launch of CAT-Spire, which represents Circassia’s first drug of a new […]

May 18, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 2 Apr 2015

Anergis completed Phase II for AllerT, a novel treatment for pollen allergies

Anergis announced treatment completion of its Phase II clinical trial of AllerT, a novel long-peptide immunotherapeutic to treat birch pollen allergies. Anergis’ approach uses synthetic, pharmaceutical-grade Contiguous Overlapping Peptide (“COP”), peptides of 40-80 amino-acids which are safer (no risk of immediate allergic reaction) and can elicit a faster immune response than the allergenic proteins they […]

April 2, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 3 Dec 2014

New Technologies Against Allergies are on the Wave

Anergis, a company developing proprietary ultra-fast allergy vaccines, closed a Series B financing round totaling 12,1 million euros. Anergis is not the only company that focuses on allergies, DBV technologies also recently raised money for its new anti-allergic patch. Allergies are the most prevalent and fastest growing chronic conditions in the industrialized world affecting over 500 million […]

December 3, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 23 Oct 2014

The First French Biotech entered successfully on the NASDAQ

DBV Technologies entered on the NASDAQ last Wednesday raising up to 90 million euros. It bets on treating peanut allergy, which is a major health issue in the United States, and targets up to one billion dollars revenues. The small French biotechnology company which has developed a new system of allergy desensitization based on skin patches launched […]

October 23, 2014 - 2 minutesmins - By Julie Lellouche

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Allergy

Peanut Allergies? This Phase III Trial Could Mean an End to Nut-Related Anaphylaxis

Swiss Biotech Boom: Life sciences startups dominate top 100 awards

DBV Technologies to cure Peanut allergy

Allergist Circassia grabs a couple of Asthma-Specialist companies

Anergis completed Phase II for AllerT, a novel treatment for pollen allergies

New Technologies Against Allergies are on the Wave

The First French Biotech entered successfully on the NASDAQ

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!